改良FOLFOX方案联合奥曲肽治疗晚期肝癌的临床疗效及安全性评价

FOLFOX combined with octreotide in the treatment of advanced hepatocellular carcinoma

目的评价改良FOLFOX方案联合奥曲肽治疗晚期肝癌的临床疗效及安全性。方法将61例晚期肝癌患者随机分为试验组30例和对照组31例。对照组给予改良FOLFOX方案化疗（奥沙利铂85 mg·m^-2静脉输注,第1,8天＋亚叶酸钙200 mg·m^-2静脉输注,第1-5天＋5-氟尿嘧啶400 mg·m^-2静脉滴注,第1-5天）;试验组在对照组的基础上,联合奥曲肽0.2 mg＋5%葡萄糖100mL静脉输注,bid。21 d为1个周期,2组患者至少接受2个以上周期化疗。比较2组患者的客观有效率、总生存期及化疗相关不良反应发生率。结果试验组客观有效率为40.00%,对照组为29.03%,2组比较差异无统计学意义（P〉0.05）;对照组和试验组1年生存率分别为46.2%和50.8%,差异无统计学意义（P〉0.05）;中位生存时间分别为11.2,12.2个月,差异无统计学意义（P〉0.05）。试验组Ⅲ-Ⅳ级白细胞减低率为6.7%,显著低于对照组的29.0%（P〈0.05）;两组间其他不良反应发生率比较,差异无统计学意义（P〉0.05）。结论改良FOLFOX方案联合奥曲肽治疗晚期肝癌可明显降低化疗相关不良反应发生率。

Objective To assess the efficacy and safety of FOLFOX combined with octreotide on advanced hepatocellular carcinoma.Methods A total of 61 cases with advanced hepatocellular carcinoma were included from February 2010 to June 2014 in our hospital and were randomly divided into control group（n=31） and treatment group（n=30）.Patients in the control group received FOLFOX chemotherapy regimen and patients in the experiment group received FOLFOX regimen combined octreotide 0.2 mg＋5%glucose 100 mL by intravenous drip,bid.21 days were a cycle.All of the patients received at least 2 cycles.The objective response rate,overall survival rate and chemotherapy related toxicity were evaluated between the two groups.Results The objective response rate was 40.00%and 29.03%respectively in the treatment group and control group without statistical difference（P〈0.05）.The 1-year survival rate was 46.2%and 50.8%in the control and experiment group without significant difference（P〈0.05）;There was no significant difference in median overall survival of control and experiment group（P〈0.05）.But the rate of chemotherapy related leukopenia was significantly lower in the Objective To assess the efficacy and safety of FOLFOX combined with octreotide on advanced hepatocellular carcinoma.Methods A total of 61 cases with advanced hepatocellular carcinoma were included from February 2010 to June 2014 in our hospital and were randomly divided into control group（n = 31） and treatment group（n = 30）.Patients in the control group received FOLFOX chemotherapy regimen and patients in the experiment group received FOLFOX regimen combined octreotide 0.2 mg ＋ 5% glucose 100 mL by intravenous drip,bid.21 days were a cycle.All of the patients received at least 2 cycles.The objective response rate,overall survival rate and chemotherapy related toxicity were evaluated between the two groups.Results The objective response rate was 40.00% and 29.03% respectively in the treatment group and control group without statistical difference（P〉0.05）.The 1-year survival rate was 46.2% and 50.8% in the control and experiment group without significant difference（P〉0.05）; There was no significant difference in median overall survival of control and experiment group（P〉0.05）.But the rate of chemotherapy related leukopenia was significantly lower in thetreatment group compared with control group（P〈0.05）.Conclusion FOLFOX combined with octreotide in the treatment of advanced hepatocellular carcinoma can significantly decrease adverse reactions.